| Trial Title | Who can participate? | Where is the trial open? | What question is the trial asking? | Trial locations | Full trial information |
|---|---|---|---|---|---|
22-16 TAORMINA: Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA)A Phase III clinical trial investigating whether adding high-dose, targeted stereotactic ablative radiation therapy (SABR) to standard systemic treatments improves outcomes for patients with limited metastatic breast cancer. |
People aged 18 or older who were diagnosed with early-stage breast cancer that had spread to the lymph nodes in the armpit can take part if, after receiving chemotherapy before surgery (called neo-adjuvant chemotherapy), their breast surgery and sentinel lymph node biopsy show no remaining cancer cells in the armpit lymph nodes. In simpler terms, this means you may be eligible if your breast cancer originally involved the armpit lymph nodes, but chemotherapy successfully cleared the cancer from those nodes before surgery. |
The trial is currently open in:
The trial is also planned to open in:
|
This study is looking at whether treating the 1-5 tumours which have spread from the breast with a special type of precise, high-dose radiation treatment, called stereotactic ablative radiotherapy (SABR),can help people live longer or do better overall. In simpler terms, the trial is testing if using SABR, which targets and destroys cancer spots with very focused radiation while sparing healthy tissue, can improve results when added to regular treatments such as chemotherapy, hormone therapy, or targeted therapy. |
Globally: Phase III European study Ireland: 4 sites |
|
CTRIAL 25-65 ATNEC: Axillary management in cT1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapyA Phase III international clinical trial investigating whether neoadjuvant chemotherapy (chemotherapy given before surgery) alone is as beneficial as neoadjuvant chemotherapy with extra armpit radiation treatment, in those patients with no remaining cancer in the armpit lymph glands after their operation. All patients on the study will receive radiation treatment to their breast area following surgery but only half of the patients will receive radiation to their armpit as part of their radiation treatment. |
People aged 18 or older who were diagnosed with early-stage breast cancer that had spread to the lymph nodes in the armpit can take part if, after receiving chemotherapy before surgery (called neo-adjuvant chemotherapy), their breast surgery and sentinel lymph node biopsy show no remaining cancer cells in the armpit lymph nodes. In simpler terms, this means you may be eligible if your breast cancer originally involved the armpit lymph nodes, but chemotherapy successfully cleared the cancer from those nodes before surgery. |
The trial is open in:
|
This study is trying to find out whether patients with no remaining cancer in their lymph glands following chemotherapy given before surgery (called neoadjuvant chemotherapy) can safely avoid radiotherapy to the armpit following their surgery. If the study shows that chemotherapy alone works just as well, then some patients may be able to avoid radiotherapy to the armpit, helping to reduce unnecessary treatment and lower the risk of long-term side effects. |
Globally: Phase III study Ireland: 7 sites |
